Recurrent Cutaneous Melanoma Hazard Rates Vary With Stage

This article originally appeared here.
Share this content:
Recurrent Cutaneous Melanoma Hazard Rates Vary With Stage
Recurrent Cutaneous Melanoma Hazard Rates Vary With Stage

(HealthDay News) – The hazard rates (HRs) for recurrent and secondary cutaneous melanoma (CM) after incident stage IA melanoma are low, while the HRs of recurrence after incident stage IB, II, and III CM are high, according to a study published in the January issue of the Journal of the American Academy of Dermatology.

Ulrike Leiter, MD, from the Eberhard Karls University in Tübingen, Germany, and colleagues investigated the stage- and time-dependent HRs for recurrent and secondary CM. From 1976 through 2007, the German Central Malignant Melanoma Registry recorded follow-up data for 33,384 patients with incident CM in stages I to III. HRs and Kaplan-Meier estimates of survival were calculated. A total of 4,999 patients had recurrences (7.1, 32.8, 51.0% in stage I, II, and III, respectively).

The investigators found that the 10-year recurrence-free survival was 78.9C overall (89.0, 56.9, and 36.0% in stage I, II, and III CM, respectively). The HR for recurrent CM was consistently low for stage IA (≤1 recurrence per 125 persons per year). The HRs were higher for stage IB for the first three years, and in general for stages II to III (≥1 recurrence per 40 persons per year). A total of 2.3% of patients developed secondary melanomas, with the HR low, at less than one recurrence per 220 persons per year.

"We propose that patients at high risk with [a] HR of more than one recurrence per 40 persons per year should be considered in an intensified follow-up schedule," the authors write.

Full Text (subscription or payment may be required)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs